Immediate-release and controlled-release carbidopa/levodopa in PD: A 5- year randomized multicenter study

Neurology

Volumn 53, Issue 5, 1999, Pages 1012-1019

  Koller, William C ^a,d   Hutton, J Thomas ^b   Tolosa, Eduardo ^c   Capilldeo, Rudy ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Neurol Res and Education Center   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

Carbidopa levodopa; Dyskinesias; Motor fluctuations; PD

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DYSKINESIA; DYSTONIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP DISORDER; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0033595549     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.5.1012     Document Type: Article

References (29)

1. Koller WC, Hubble JP. Levodopa therapy in Parkinson's disease. Neurology 1990;40:40-47.
2. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurology 1996;47:146-152.
3. Poewe WH. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology 1994;44:6-9.
4. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's Disease. Carnforth: Parthenon Publishing Group, 1992: 89-112.
5. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29:1252-1260.
6. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson's disease. Neurology 1981;31:125-131.
7. Sage JL, Mark MH. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Neurology 1992;42:33-38.
8. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
9. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(suppl):15-18.
10. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part I. Ann Neurol 1988;24: 366-371.
11. Nutt JG. On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22:535-540.
12. Block G, Liss C, Reiner S, et al. Comparison of immediate-release and controlled-release carbidopa-levodopa in Parkinson's disease. Eur Neurol 1997;37:23-27.
13. Koller WC. Handbook of Parkinson's disease. New York: Marcell Dekker, 1982:475-490.
14. Fahn S, Eton RL, and members of the UPDRS Development Committee: Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al., eds. Recent developments in Parkinson's disease. Part II. Florham Park, NJ: MacMillan Healthcare Information, 1987.
15. Hunt SM, McEwen J, McKenna SP. Measuring health status. London: Croom Helm, 1986.
16. Yeh KC, August MS, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39:25-38.
17. Lee CS, Schulzer M, Mak K, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994; 117:501-507.
18. Goetz CG, Tanner CM, Shannon KM. Progression of Parkinson's disease without levodopa. Neurology 1987;37:695-698.
19. Bonnet AM, Loria Y, Saint-Hilaire MH. et al. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-1542.
20. Rajput AH, Stern W, Lawerty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
21. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; i:292-296.
22. Barbeau A, Roy M. Six-year results of treatment with levodopa plus benserazide in Parkinson's disease. Neurology 1976; 26:399-404.
23. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson's disease. Neurology 1991;41:622-629.
24. Caraceni T, Seigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384.
25. Parkinson's Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
26. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226.
27. Goetz CG, Tanner CM, Stebbins GT, et al. Risk factors for progression in Parkinson's disease. Neurology 1988;38:1841-1844.
28. Rinne UK, Rinne OG. Madopar HBS in the treatment of early Parkinson's disease. In: Agroli A, Campanella C, eds. New developments in the treatment of Parkinson's disease. Rome: Libbey 1991:16-21.
29. DuPont E, Anderson A, Bors J, et al. Sustained-release Madopar HBS compared to standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996;93:14-20.